glp 1 help with perimenopause GLP-1 Medications & Perimenopause: or Harm? The Complete GLP-1 Guide for

Any papers resulting from these two trials do not appear to be indexed in major global databases like PubMed, and its not clear if they were ever published in peer-reviewed journals

In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)

The genetic basis of AS leads to structural and functional disruptions of the glomerular basement membrane (GBM), driving early-onset fibrosis and inflammation

(PubMed) Luo T, Li J, Li L, et al

In addition to weight loss, drugmakers have promoted such purported ancillary benefits as reduced risk of heart disease and type 2 diabetes